Back to the main directory
EarningsReview / Equity
- DSV (Buy, TP: DKK1400.00) - Forecast sequential EBIT growth by DnB Markets
- Husqvarna Minor model adjustments by DnB Markets
- A bumpy road trip ahead by BNP Paribas Exane
- Atrium Ljungberg - Sell/SEK 193 (180): Hold your horses by Nordea
- Don’t be down on your truck, it’s only a flat tyre by BNP Paribas Exane
- Medical emergency by BNP Paribas Exane
- JM - Starts are up, supported by higher sales rates by Danske Bank Equity Research
- Lepermislibre - Priorité aux marges au détriment de la croissance by MidCap Partners
- Lepermislibre - Focus on margins at the expense of growth by MidCap Partners
- INVEST SECURITIES - AUDACIA : En bonne voie pour réussir son pari audacieux - ACHAT, OC 9,6€ vs 10,5€ by Invest Securities
- 德邦股份（603056 CH） by HSBC
- Non material data changes by BNP Paribas Exane
- Mixed 2Q24 Print: FY24 Organic Sales Growth Guide Edged Lower (Again), EPS Reaffirmed by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Tylenol Litigation Update by BNP Paribas Exane
- Recce Pharmaceuticals - Taking a closer look at diabetic foot infections by Edison Investment Research
- 2024 Pressure Points (Part 1) - FSLR, GEV, ENPH, SEDG, FLNC by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Largan Precision (3008 TT) by HSBC
- Growth recovery broadening by BNP Paribas Exane
- Allowed return for UK water in-line, devil in the details by BNP Paribas Exane
- WSM Intra-quarter catchup: our key takeaways by BNP Paribas Exane
- 2020 Bulkers (Sell, TP: NOK149.00) - Top performer in murky sector by DnB Markets
- OKEA (Hold, TP: NOK23.00) - Elevated risk at Statfjord by DnB Markets
- Genmab (Buy, TP: DKK2600.00) - 2024 guidance likely to be revised by DnB Markets